ライフサイエンスコーパス: uveal melanoma

1 TILs) could mediate regression of metastatic uveal melanoma.

2 umour regression in patients with metastatic uveal melanoma.

3 RAB31 was a predictor of metastasis risk in uveal melanoma.

4 lps determine the diagnosis and prognosis in uveal melanoma.

5 protein-1 gene (BAP1) predispose carriers to uveal melanoma.

6 ion retinopathy and alternative therapies of uveal melanoma.

7 etected in 2 of 8 families with a history of uveal melanoma.

8 ptomatic metastases in patients with primary uveal melanoma.

9 stemic surveillance in patients with primary uveal melanoma.

10 e, 2131 deaths were the result of metastatic uveal melanoma.

11 nti-cMET monoclonal antibodies in metastatic uveal melanoma.

12 embers of this kindred reported a history of uveal melanoma.

13 r exploited as a biomarker for monitoring of uveal melanoma.

14 the initiation and metastatic progression of uveal melanoma.

15 esized to play a role in the pathogenesis of uveal melanoma.

16 cificity in the identification of metastatic uveal melanoma.

17 protein 1 gene) are frequently identified in uveal melanoma.

18 edition of the AJCCCancer Staging Manual for uveal melanoma.

19 tient-specific data fields for patients with uveal melanoma.

20 ng the standard of care in the management of uveal melanoma.

21 overall survival in patients with metastatic uveal melanoma.

22 thought to occur early in the development of uveal melanoma.

23 ars to be a prognostic factor for death from uveal melanoma.

24 individual prediction model of survival from uveal melanoma.

25 -year period of 47 consecutive patients with uveal melanoma.

26 ng response to targeted molecular therapy in uveal melanoma.

27 e targeted molecular agents in patients with uveal melanoma.

28 ccination is feasible and safe in metastatic uveal melanoma.

29 n on 5-year risk of death after diagnosis of uveal melanoma.

30 is not recommended as a prognostic marker in uveal melanoma.

31 resolution after brachytherapy of posterior uveal melanoma.

32 cancer cells as well as Galpha(q/11) mutated uveal melanoma.

33 be made for or against specific therapy for uveal melanoma.

34 x of the GEP test in patients with posterior uveal melanoma.

35 hods in uveal tract disorders, especially in uveal melanoma.

36 ther showed that vitamin D is metabolized in uveal melanoma.

37 of BET inhibition in patients with advanced uveal melanoma.

38 sduction axis is crucial for tumor growth in uveal melanoma.

39 DOTA-MC1RL as a novel therapy for metastatic uveal melanoma.

40 of these targeted therapies in patients with uveal melanoma.

41 led for enucleation as primary treatment for uveal melanoma.

42 A total of 1059 patients with uveal melanoma.

43 a promising potential therapeutic target in uveal melanoma.

44 cinoma, mesothelioma and meningioma, but not uveal melanoma.

45 D147 and MMP-2 was analyzed in 49 samples of uveal melanomas.

46 d MMP-2 were expressed in 47 (96.0 %) of the uveal melanomas.

47 ha and RORgamma in the human uveal tract and uveal melanomas.

48 tely half of the patients died of metastatic uveal melanoma (10-year rate, 48.5%; 95% CI, 43.0%-54.4%

49 uveal melanoma xenografts, 57 patients with uveal melanoma (17 patients whose tumors metastasized an

50 From 732 patients diagnosed with uveal melanoma, 311 were treated with brachytherapy.

51 atients treated with plaque radiotherapy for uveal melanoma, 73 (1%) developed radiotherapy-induced s

52 y period 515 enucleations were performed for uveal melanoma, 99 (19%) of which were secondary enuclea

53 aluated the mechanisms of BETi resistance in uveal melanoma, a disease with little treatment options,

54 ying YAP as a suitable therapeutic target in uveal melanoma, a GNAQ/GNA11-initiated human malignancy.

55 For diagnostic biopsy of uveal melanoma, a larger-gauge needle or a 27 G vitrecto

56 aluated 48 patients with local recurrence of uveal melanoma after primary treatment with brachytherap

57 s known about the long-term risk of dying of uveal melanoma after treatment with radiotherapy.

58 52 studies, reporting on 1010 patients with uveal melanoma and 34 intraocular metastases, were eligi

59 ent selection criteria included diagnosis of uveal melanoma and adequate records to allow tumor stagi

60 ermline BAP1 mutations occur infrequently in uveal melanoma and are associated with larger tumors and

61 ntervals (95%CIs) with respect to death from uveal melanoma and death from all causes.

62 concepts of the cytogenetic pathogenesis of uveal melanoma and demonstrate the potential problems an

63 t is the most robust prognostic indicator in uveal melanoma and early studies of mostly larger tumors

64 responses were observed in one patient with uveal melanoma and four of 15 evaluable patients with RC

65 issense variants we identified are common in uveal melanoma and have been shown to constitutively act

66 between the BAP1 immunoreactivity of primary uveal melanoma and other clinicopathologic features.

67 t intraocular tumors in adults and children (uveal melanoma and retinoblastoma, respectively).

68 Clinical characteristics of uveal melanoma and the development of metastases.

69 expression with major prognostic factors for uveal melanoma and the development of metastasis.

70 Choroidal nevus is a precursor for uveal melanoma and there are no known risk factors besid

71 is an efficacious primary method of treating uveal melanomas and intraocular metastases, with reliabl

72 mutations are predominantly associated with uveal melanomas and mesotheliomas.

73 omplications of gamma knife radiosurgery for uveal melanomas and metastases.

74 ormed multi-region DNA sequencing of primary uveal melanomas and their matched metastases from 35 pat

75 alpha subunits, are the driver oncogenes in uveal melanoma, and mutations in Gq-linked G protein-cou

76 eir lifetime, mostly malignant mesothelioma, uveal melanoma, and so on.

77 enase [LDH]) perform poorly in patients with uveal melanoma, and the search for new biomarkers is nee

78 uveal melanoma; iii) metastasizing disomy 3 uveal melanoma; and iv) monosomy 3 uveal melanoma with l

79 Recent advances in the molecular genetics of uveal melanoma are revolutionizing our understanding of

80 Uveal melanomas are molecularly distinct from cutaneous

81 In Finland, uveal melanomas are treated centrally in the Ocular Onco

82 Patients with uveal melanoma associated with oculo(dermal) melanocytos

83 edictive of metastasis in patients harboring uveal melanoma associated with oculo(dermal) melanocytos

84 mber 2013 among 120 patients with metastatic uveal melanoma at 15 academic oncology centers in the Un

85 Sampling of a clinically diagnosed posterior uveal melanoma at a single site for prognostic GEP testi

86 treated with primary proton beam therapy for uveal melanoma at the oncology service at Charite-Berlin

87 Early detection of posterior uveal melanoma, at a point when the tumor is small, can

88 lopment of a new molecular classification of uveal melanoma based on a widely available 15-gene expre

89 All were referred because of suspected uveal melanoma, based on ultrasonographic imaging.

90 linical macular edema is common in eyes with uveal melanoma before and at 4 months after plaque radio

91 indicated only in case of re-recurrences of uveal melanoma, but not because of secondary complicatio

92 GNAQ and GNA11 are frequently mutated in uveal melanoma, but they remain difficult therapeutic ta

93 Quantification of the risk of developing uveal melanoma can enhance counseling regarding surveill

94 In comparison, uveal melanoma cases with BAP1 germline pathogenic varia

95 Levels of sc-Met in uveal melanoma cell cultures and in the blood serum samp

96 t was studied in the conditioned medium of 9 uveal melanoma cell lines and in the blood serum samples

97 The conditioned medium of uveal melanoma cell lines and the blood serum samples of

98 The TSN from uveal melanoma cell lines is capable of affecting the ch

99 resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibito

100 ARF6 with a small-molecule inhibitor reduces uveal melanoma cell proliferation and tumorigenesis in a

101 ere, in a series of experiments, using human uveal melanoma cells (MEL 270), human embryonic kidney c

102 No significant cell shearing of uveal melanoma cells occurred in vitro with 25 G, 27 G,

103 Exposure of freshly cultured uveal melanoma cells to hypoxia led to an increased expr

104 kappaB inhibitors synergistically sensitized uveal melanoma cells to PLX51107 treatment.

105 Survival of uveal melanoma cells was evaluated in vitro following ne

106 bility and for MC1R-specific cytotoxicity in uveal melanoma cells, and the lanthanum-DOTA-MC1RL analo

107 Galphaq promotes the YAP-dependent growth of uveal melanoma cells, thereby identifying YAP as a suita

108 ate that CD147 regulates MMP-2 expression in uveal melanoma cells.

109 differentially expressed in cultured primary uveal melanoma cells.

110 Compared with uveal melanoma classified as AJCC stage I, the rate of m

111 Compared with uveal melanoma classified as T1, the rate of metastasis

112 Survival of patients with uveal melanoma classified to have a bad prognosis.

113 ted variability in survival of patients with uveal melanoma classified to have a bad prognosis.

114 ic FNAB had an unequivocal primary posterior uveal melanoma clinically, while patients who underwent

115 The TSN of 1 cell line and 2 primary uveal melanoma cultures inhibited the dendritic cell mat

116 From the Wills Eye Hospital Oncology Service Uveal Melanoma Cytogenetic Database (N = 1172), 128 pati

117 shed new light on the molecular genetics of uveal melanoma, delineating it as an atypical tumor of t

118 every 4 months after plaque radiotherapy for uveal melanoma demonstrated OCT-evident macular edema, c

119 , whereas somatic Galpha11 mutations mediate uveal melanoma development by constitutively up-regulati

120 ) in patients undergoing prognostication for uveal melanoma does not exist.

121 ice, of healthy donors, and of patients with uveal melanoma during follow-up.

122 our patients developed nonorbital metastatic uveal melanoma during the study period.

123 high local tumor control rates in recurrent uveal melanoma, especially if the primary therapy was tr

124 ondition that can lead to the development of uveal melanoma, estimated at 1 in 400 affected patients.

125 astatic death in 299 patients with posterior uveal melanoma evaluated by fine-needle aspiration biops

126 Patients diagnosed with uveal melanoma from 1995 to 2016 and treated with episcl

127 ent selection criteria included diagnosis of uveal melanoma from April 1, 2001, to April 1, 2011, ade

128 with episcleral brachytherapy for posterior uveal melanoma from January 2004 to December 2014.

129 All patients with a clinical diagnosis of uveal melanoma from May 2009 to July 2013 who underwent

130 on, and assessed the effect of NPS-2143 on a uveal melanoma Galpha11 mutant.

131 The probability of uveal melanoma given that BAP1 mutation exists was deriv

132 ing brachytherapy in patients with posterior uveal melanoma, given that an understanding of the recur

133 One patient without a family history of uveal melanoma had a single nucleotide substitution in t

134 date, the role of germline BAP1 mutations in uveal melanoma has not been characterized.

135 Metastatic uveal melanoma has poor overall survival (OS) and no app

136 The treatment of uveal melanoma has seen a shift towards eye conserving t

137 The techniques for assessing prognosis in uveal melanoma have evolved from simple physical feature

138 n is a promising treatment for patients with uveal melanoma hepatic metastases.

139 r molecular prognostication in patients with uveal melanoma; however, class 1 and class 2 test result

140 te four clinically well-defined subgroups of uveal melanoma: i) disomy 3 uveal melanoma with long-ter

141 his analysis, we included 3088 patients with uveal melanoma, identified from a hospital-based cohort

142 etecting metastases in patients with primary uveal melanoma, if combined with LFT and, in case of any

143 -term survival; ii) metastasizing monosomy 3 uveal melanoma; iii) metastasizing disomy 3 uveal melano

144 Conditional survival estimates of uveal melanoma improve with time since primary diagnosis

145 se patients from 6 families had a history of uveal melanoma in 1 relative, and 2 patients from 2 addi

146 cause of death was metastatic disease due to uveal melanoma in 561 patients.

147 nhance the host's antitumor immunity against uveal melanoma in approximately one third of patients.

148 Both had a family history of uveal melanoma in at least 1 relative.

149 ons between vitamin D signaling elements and uveal melanoma in comparison to uveal tract encourage fu

150 The point prevalence of uveal melanoma in patients with the germline BAP1 pathog

151 The number with uveal melanoma in PES studies has been small.

152 ents who underwent secondary enucleation for uveal melanoma in the London Ocular Oncology Service, be

153 naling pathways in the human uveal tract and uveal melanoma, including analysis of the expression of

154 d, repeatable system for dividing metastatic uveal melanoma into distinct prognostic subgroups, espec

155 A diagnosis of choroidal melanoma (ie, any uveal melanoma involving the choroid).

156 Uveal melanoma is a clinically distinct and particularly

157 Uveal melanoma is a rare tumour with no established trea

158 Uveal melanoma is a serious life-threatening intraocular

159 pression of the oncoprotein c-Met in primary uveal melanoma is associated with metastatic progression

160 Uveal melanoma is characterized by mutations in GNAQ and

161 loss following episcleral brachytherapy for uveal melanoma is difficult to predict for individual pa

162 results challenge the belief that metastatic uveal melanoma is immunotherapy resistant and support th

163 germline BAP1 pathogenic variant given that uveal melanoma is present.

164 Uveal melanoma is the most common eye cancer in adults a

165 Uveal melanoma is the most common primary cancer of the

166 Uveal melanoma is the most common primary intraocular ma

167 mary orbital conjunctiva melanoma-like and a uveal melanoma-like group.

168 ion regarding the long-term risk of dying of uveal melanoma may be useful to clinicians when counseli

169 Forty patients with uveal melanoma (mean age, 57.98+/-14.75 years) were incl

170 Our study indicated that the uveal melanoma melanin level inversely correlated with V

171 ted protein-1 (BAP1) gene has been linked to uveal melanoma, mesothelioma, meningioma, renal cell car

172 tin 1 receptor (MC1R) is expressed in 94% of uveal melanoma metastases, and a MC1R-specific ligand (M

173 Survival of patients with uveal melanoma metastatic to the liver correlates strong

174 SIRT as first-line therapy in patients with uveal melanoma metastatic to the liver.

175 produced promising outcomes in patients with uveal melanoma metastatic to the liver.

176 ERK phosphorylation associated with ADH2 and uveal melanoma mutants was rectified by NPS-2143.

177 lignancies among BAP1 mutation carriers were uveal melanoma (n = 60 [28%]), mesothelioma (n = 48 [22%

178 Patients undergoing enucleation for uveal melanoma need to be informed of the possibility of

179 tosis group was matched with 2 patients with uveal melanoma not associated with ocular melanocytosis

180 Our findings implicate CYSLTR2 as a uveal melanoma oncogene and highlight the critical role

181 of certain heterotrimeric G proteins, drive uveal melanoma oncogenesis by triggering multiple downst

182 mutually exclusive pattern in most cases of uveal melanoma, one of the most aggressive cancers.

183 knife radiosurgery as primary treatment for uveal melanoma or uveal metastases.

184 egate the clinical outcomes of patients with uveal melanomas or intraocular metastases treated primar

185 onsecutive patients diagnosed with posterior uveal melanoma over a 5-year period who were evaluated w

186 ht the critical role of Galphaq signaling in uveal melanoma pathogenesis.

187 A committee was formed to create uveal melanoma patient-specific data fields.

188 oma specific mortality among newly diagnosed uveal melanoma patients after five years.

189 rm outcomes concerning globe preservation in uveal melanoma patients after proton beam therapy with t

190 in vivo and a subset of liver metastases of uveal melanoma patients express activated forms of ERBB2

191 atment and long-term surveillance of treated uveal melanoma patients is necessary.

192 The age at diagnosis and the gender of the uveal melanoma patients with BAP1 germline pathogenic va

193 Uveal melanoma patients with ischemic retinal detachment

194 Uveal melanoma patients with metastatic disease usually

195 but show only modest efficacy in metastatic uveal melanoma patients.

196 on exists was derived from the prevalence of uveal melanoma, prevalence of germline BAP1 pathogenic v

197 ecent discovery of major driver mutations in uveal melanoma provide a rational basis for development

198 ee on Cancer's 7th Edition Classification of Uveal Melanoma," published online January 2, 2015, in JA

199 erapy (EPBT) for locally recurrent posterior uveal melanoma (PUM).

200 Patients with metastatic uveal melanoma received at least 3 vaccinations with aut

201 e 3, 2003, and March 18, 2008, patients with uveal melanoma received SDRT monotherapy (group 1, 60 pa

202 To determine the personalized rate of uveal melanoma-related metastasis on the basis of indivi

203 Of 1059 patients with uveal melanoma sampled for status of chromosomes 3, 6, a

204 We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in

205 of proinflammatory genes in freshly cultured uveal melanoma samples was studied in an in vitro 24-hou

206 s-generating study of patients with advanced uveal melanoma, selumetinib compared with chemotherapy r

207 or-associated lymphocytes, most prominent in uveal melanoma, showed positive results for PAX8.

208 To examine the all-cause mortality and uveal melanoma specific mortality among newly diagnosed

209 We report our experience with uveal melanoma-specific gene expression profile (GEP) te

210 edle aspiration biopsy for cytopathology and uveal melanoma-specific GEP testing for molecular progno

211 The 5-year uveal melanoma-specific survival probability was 82.9% (

212 Although an accurate uveal melanoma staging system is needed to improve resea

213 BRD9 is a potent tumour suppressor in uveal melanoma, such that correcting mis-splicing of BRD

214 Among the characteristics of uveal melanoma that are associated with a poor prognosis

215 tereotactic radiotherapy in the treatment of uveal melanoma that cannot be handled with ruthenium-bra

216 Of 7731 patients with posterior uveal melanoma, the AJCC classification based on T was c

217 Patient 1 had metastatic uveal melanoma; the findings resolved without interventi

218 BAP1 immunohistochemical staining of primary uveal melanoma to evaluate metastatic risk.

219 e after I-125 brachytherapy in patients with uveal melanoma treated and followed in a Spanish referra

220 ospective chart review of 7872 patients with uveal melanoma treated at the Ocular Oncology Service, W

221 dy reviewing data from patients with primary uveal melanoma treated between October 2003 and October

222 nd histology slides of patients with primary uveal melanoma treated by enucleation were reviewed.

223 We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination.

224 Patients with uveal melanoma treated with plaque radiotherapy were div

225 onic lymphocytic leukemia, breast cancer and uveal melanoma tumor samples, we show that hundreds of c

226 Severe combined immunodeficient mice bearing uveal melanoma tumors or engineered MC1R-positive and -n

227 Uveal melanoma (UM) can be divided into prognostically s

228 e of genetic risk factors in the etiology of uveal melanoma (UM) has been strongly suggested, the gen

229 ound Overall survival (OS) for patients with uveal melanoma (UM) hepatic metastases is extremely poor

230 expression profile (GEP) testing segregates uveal melanoma (UM) into 2 main prognostic classes.

231 Uveal melanoma (UM) is a currently untreatable form of m

232 Uveal melanoma (UM) is a genetically and biologically di

233 Uveal melanoma (UM) is a highly metastatic cancer that,

234 Human uveal melanoma (UM) is a major ocular malignant tumor wi

235 Uveal melanoma (UM) is a rare intraocular tumor that, si

236 Uveal melanoma (UM) is an aggressive tumor in which appr

237 Uveal melanoma (UM) is the most common cancer in adult e

238 Uveal melanoma (UM) is the most common intraocular tumou

239 Uveal melanoma (UM) is the most common primary intraocul

240 Uveal melanoma (UM) is the most common primary intraocul

241 Uveal melanoma (UM) is unique among cancers in displayin

242 (TCGA) classification has been validated for uveal melanoma (UM) prognostication.

243 istopathologic growth patterns of metastatic uveal melanoma (UM) to the liver.

244 Uveal melanoma (UM) was a fatal malignancy in 40% to 50%

245 eration (SCD) has been observed in eyes with uveal melanoma (UM), but, to our knowledge, a definitive

246 n 1 (BAP1) are associated with metastasis in uveal melanoma (UM), the deadliest adult eye cancer.

247 11) proteins, occur in about 85% of cases of uveal melanoma (UM), the most common cancer of the adult

248 describe the unique accumulation of cases of uveal melanoma (UM).

249 proteins, are initiating oncogenic events in uveal melanoma (UM).

250 ring the human eIF1A NTT are associated with uveal melanoma (UM).

251 e been described in the following 5 genes in uveal melanoma (UM): BAP1, EIF1AX, GNA11, GNAQ, and SF3B

252 Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinc

253 tions in GNAQ or GNA11 occurs in over 80% of uveal melanomas (UMs) and activates MAPK.

254 is associated with more benign behavior for uveal melanomas (UMs) with an otherwise high risk of met

255 BASE for studies reporting survival data for uveal melanoma undergoing prognostic testing with chromo

256 sc-Met levels in patients with nonmetastatic uveal melanoma vs patients with metastatic uveal melanom

257 Metastasis of uveal melanoma was 2.8 times higher in patients with iri

258 quencing from blood samples of patients with uveal melanoma was correlated with clinical characterist

259 cleral necrosis after plaque radiotherapy of uveal melanoma was detected in 1% of cases.

260 Two hundred fifteen patients whose primary uveal melanoma was managed in the Helsinki University Ho

261 nts aged 45 to 79 years with newly diagnosed uveal melanoma was recruited between 2002 and 2004 from

262 EER database, the median age at diagnosis of uveal melanomas was 63 (range 3-99 years) with a male-to

263 The cytologic characteristics of uveal melanoma were analyzed for 150 consecutive patient

264 Main prognostic factors for the death of uveal melanoma were ciliary body involvement (HR: 1.7 (9

265 l of 21 consecutive patients with metastatic uveal melanoma were enrolled between June 7, 2013, and S

266 y, patients with melanocytosis who developed uveal melanoma were found to have double the risk for me

267 None of the mutations associated with uveal melanoma were found.

268 A total of 6863 cases of uveal melanoma were identified.

269 ients who underwent plaque brachytherapy for uveal melanoma were included.

270 tant Galpha11 proteins causing FHH2, ADH2 or uveal melanoma were transfected in CaSR-expressing HEK29

271 Seventy-eight patients with uveal melanoma were treated.

272 Indications for secondary enucleations for uveal melanoma were tumor recurrence, neovascular glauco

273 ntroduce the first transgenic mouse model of uveal melanoma, which develops cancers induced by expres

274 therapies are greatly needed for metastatic uveal melanoma, which has a very poor prognosis with a m

275 ariants in consecutive Finnish patients with uveal melanoma who come from a high-risk region for the

276 logy referral center among 507 patients with uveal melanoma who consented for collection of blood sam

277 ic variants of BAP1 in Finnish patients with uveal melanoma who live in a high-risk region for this c

278 survival in high-risk patients with primary uveal melanoma who received adjuvant sunitinib with inst

279 ce of 96 patients with clinical diagnosis of uveal melanoma who underwent prognostication at the time

280 Patients with uveal melanoma who underwent transscleral or transvitrea

281 cutive patients with a clinical diagnosis of uveal melanoma who were treated at the Cleveland Clinic

282 Variability exists in reported survival for uveal melanoma with a bad prognosis.

283 metastasis differs in patients with primary uveal melanoma with different grades of nuclear BAP1 imm

284 sion was found to be a peripapillary primary uveal melanoma with distinct non-pigmented and pigmented

285 All patients had a diagnosis of treated uveal melanoma with documented tumor control.

286 al was significantly longer in patients with uveal melanoma with high nuclear BAP1 stain (P = 0.004).

287 in patients treated with proton therapy for uveal melanoma with ischemic retinal detachment prevente

288 Ninety-six patients affected by posterior uveal melanoma with large exudative retinal detachment (

289 disomy 3 uveal melanoma; and iv) monosomy 3 uveal melanoma with long-term survival.

290 ned subgroups of uveal melanoma: i) disomy 3 uveal melanoma with long-term survival; ii) metastasizin

291 sforming our understanding and management of uveal melanoma with the ultimate goal of improving patie

292 nal experience with plaque brachytherapy for uveal melanomas with a focus on local control rates, fac

293 iogenesis was present in the ciliary body in uveal melanomas with and without extraocular extension,

294 Uveal melanomas with BAP1 mutations demonstrate sensitiv

295 ilimumab demonstrates activity in metastatic uveal melanoma, with deep and sustained confirmed respon

296 iated protein-1 (BAP1) expression of primary uveal melanomas without and with metastasis, and to anal

297 nes and the blood serum samples of mice with uveal melanoma xenografts contained significant levels o

298 Uveal melanoma xenografts growing in the liver in vivo a

299 d in the blood serum samples of 24 mice with uveal melanoma xenografts, 57 patients with uveal melano

300 c uveal melanoma vs patients with metastatic uveal melanoma yielded an area under the curve of 0.82 (